Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Obesity

FDA: Weight-Loss Drug Possibly Linked to Cancer

Diana Ernst, RPh

January 16, 2020

Lorcaserin may potentially increase the risk of cancer, according to results from a clinical trial assessing the safety of the weight loss agent.

General Endocrinology

Experts Weigh In on the Best Diets for 2020

Diana Ernst, RPh

January 10, 2020

For those looking for a quick fix, the HMR Program was ranked number one for fast weight loss.

Pediatric Endocrinology

FDA Approves Mealtime Insulin Option for Pediatric Patients With Diabetes

Diana Ernst, RPh

January 9, 2020

The approval was based on data from an active-controlled, treat-to-target trial (Onset7) that included 777 pediatric patients (aged 2 to 17 years) with type 1 diabetes.

Diabetes

Programs to Improve Insulin Affordability Launched in United States

Diana Ernst, RPh

January 6, 2020

Novo Nordisk announced the launch of several new programs that are intended to improve insulin affordability for US patients. These programs include: My$99Insulin: Patients will be allowed to purchase up to 3 vials or 2 packs of FlexPen/FlexTouch/PenFill pens of any combination of Novo Nordisk insulins (ie, NovoLog, Novolog Mix 70/30, Levemir, Tresiba, Fiasp, Novolin…

First App Launched to Identify Drug Shortages

Thyroid

FDA Panel Votes on Teprotumumab for Thyroid Eye Disease

Diana Ernst, RPh

December 19, 2019

The Food and Drug Administration (FDA)’s Dermatologic and Ophthalmic Drugs Advisory Committee voted in favor of the approval of teprotumumab (Horizon Therapeutics) for the treatment of thyroid eye disease.

Diabetes

FDA: NDMA Identified in Common Diabetes Drug Outside of United States

Diana Ernst, RPh

December 10, 2019

The FDA is investigating metformin products in the US based on these reports; currently no metformin products have been recalled.

General Endocrinology

New Formulation of Tesamorelin Available for Patients With HIV and Lipodystrophy

Diana Ernst, RPh

December 3, 2019

Egrifta SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Cardiovascular and Metabolic Disorders

Twice-Yearly Dosing of Inclisiran Provides Significant LDL-C Lowering

Diana Ernst, RPh

November 22, 2019

Twice-yearly dosing with inclisiran sodium resulted in significant lowering of low-density lipoprotein cholesterol, according to results from the ORION-9 study.

Type 2 Diabetes

Reduced Risk for HF Hospitalization With Empagliflozin vs Other Antidiabetic Agents

Diana Ernst, RPh

November 21, 2019

Treatment with empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, was associated with reduced risk of hospitalization for heart failure when compared with use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide (GLP)-1 receptor agonists.

Cardiovascular and Metabolic Disorders

FDA Panel Votes on Vascepa for Cardiovascular Risk Reduction

Diana Ernst, RPh

November 20, 2019

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted in favor (16-0) to recommend the approval of Vascepa (icosapent ethyl capsules; Amarin) to reduce residual cardiovascular (CV) risk in patients with statin-managed low density lipoprotein (LDL) cholesterol, but persistent elevated triglycerides.

Next post in Cardiovascular and Metabolic Disorders